DADC
XLRN

D.A. Davidson & Co’s Acceleron Pharma XLRN Stock Holding History

D.A. Davidson & Co’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,861
Closed -$56K – 2139
2017
Q2 		$56K Sell
1,861
-122
-6% -$3.54K ﹤0.01% 1498
2017
Q1 		$52K Sell
1,983
-309
-13% -$8.14K ﹤0.01% 1507
2016
Q4 		$57K Sell
2,292
-44
-2% -$1.39K ﹤0.01% 1547
2016
Q3 		$84K Sell
2,336
-2
-0.1% -$66 ﹤0.01% 1296
2016
Q2 		$78K Buy
2,338
+36
+2% +$1.17K ﹤0.01% 1228
2016
Q1 		$60K Buy
2,302
+71
+3% +$2.06K ﹤0.01% 1328
2015
Q4 		$108K Hold
2,231
– – ﹤0.01% 1090
2015
Q3 		$55K Buy
2,231
+4
+0.2% +$120 ﹤0.01% 1328
2015
Q2 		$70K Buy
+2,227
New +$71.9K ﹤0.01% 1293

Other funds holding XLRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

D.A. Davidson & Co's XLRN Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Acceleron Pharma (XLRN) in Q3 2017, closing a stake of 1,861 shares — an estimated $56K sold.

D.A. Davidson & Co first reported a position in XLRN in Q2 2015 and held it in 9 quarters. The position peaked at $108K in Q4 2015. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Acceleron Pharma position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,861 Acceleron Pharma shares in Q3 2017, an estimated $56K.
  • D.A. Davidson & Co first reported a position in Acceleron Pharma in Q2 2015 and held it in 9 quarters.
  • D.A. Davidson & Co's Acceleron Pharma position peaked at $108K in Q4 2015.
  • 149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.